RxDoctor Payments Data

Russell Huang, MD

Glaucoma Specialist · Bethesda, MDNPI 1437540119

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,939 of the $2,583 with a category attached, or 75.1%. 14 manufacturers reported payments, led by AbbVie at 38.1% of the total.

$2,583in general payments, 2019–2025

Across 35 payments — averaging $73.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$985
  • Johnson & Johnson Surgical Vision, Inc.$354
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$290
  • Sight Sciences, Inc.$224
  • NEW World Medical,inc.$211
  • Oyster Point Pharma, Inc.$108
  • plus $410 from 8 others

What the payments were for

  • Travel & lodging$64425%
  • Food & beverage$1,93975%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$443,019
Medicare patients
915
Services billed
4,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine14$9,527
RhopressaNetarsudil Mesylate20$6,850
RocklatanNetarsudil Mesylat/Latanoprost17$6,786
Prednisolone Acetate73$3,294
Latanoprost203$1,930
Brimonidine Tartrate62$1,711
Dorzolamide-TimololDorzolamide/Timolol/Pf16$1,195
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat60$990
Ketorolac Tromethamine43$877
Dorzolamide Hcl21$518
Timolol Maleate30$421
ErythromycinErythromycin Base21$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$22$13,63637 claims
AbbVieRestasis$985$9,52714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Marylandon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Bethesda

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →